RSNA 2019 News

FDA OKs Bracco's ultrasound enhancing agent

By staff writers
December 4, 2019

Contrast developer Bracco Diagnostics announced its contrast agent Lumason is the first ultrasound enhancing agent to obtain U.S. Food and Drug Administration (FDA) clearance for use in echocardiography to opacify the left ventricular chamber. The agent also improves the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms.

Lumason is distributed globally outside the U.S. as SonoVue and has been marketed since 2001 for use in adult populations.

In other Bracco news, an experimental artificial intelligence study of two gadolinium-based contrast agents found that ProHance (gadoteridol) at 279.3 mg/mL and Gadavist provided a similar degree and pattern of contrast enhancement in brain MR images. The study specifically looked at patients with glioblastoma multiforme previously enrolled in a large-scale, multicenter, randomized, double-blinded controlled clinical study (TRUTH study).

Each of the 32 patients with glioblastoma multiforme received both ProHance contrast and Gadavist contrast in a double-blind, randomized crossover method. The images were evaluated in a blinded fashion using a layered machine-learning system. Enhancement characteristics for both agents were processed and the differences for each set of image pairs were calculated and analyzed.

In the 27 evaluable patients, the machine-learning system found no statistically significant difference in enhancement characteristics between the standard concentration of ProHance contrast and the double concentration of Gadavist contrast.

Full study results will be presented at RSNA 2019 in Chicago.

Decision in Bracco-Jubilant case under review
The U.S. International Trade Commission has agreed to review a ruling by an administrative law judge that Jubilant DraxImage did not violate unfair competition...
Bracco scores FDA approval for barium swallow contrast
Bracco Diagnostics, subsidiary of contrast developer Bracco Imaging, has received U.S. Food and Drug Administration (FDA) approval for the use of its...
Bracco highlights research affirming Lumason safety
Bracco Diagnostics, subsidiary of contrast developer Bracco Imaging, is promoting the results of a new study demonstrating that its Lumason ultrasound...
Bracco to acquire Blue Earth Diagnostics
Contrast developer Bracco Imaging has signed a definitive agreement to acquire molecular imaging firm Blue Earth Diagnostics for $450 million, with...
Bracco grants kids' hospital $300K for contrast ultrasound
Contrast developer Bracco Imaging has granted Children's Hospital of Philadelphia $300,000 to fund research and educate physicians and technologists to...

Copyright © 2019

Last Updated np 12/4/2019 12:40:13 PM